Safety and therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at Shecha health centre, Arba Minch, Ethiopia

Malaria Journal

Research

Anteneh Kassahun Mare¹  Solomon Mequanente Abay¹  Kale Gubae²  Mebrahtom Haile³  Gudissa Assefa³  Geremew Tasew⁴  Bokretsion Gidey⁴  Heven Sime⁴  Hussein Mohammed⁴  Henok Hailgiorgis⁴  Ashenafi Assefa⁵  Worku Bekele⁶ 

[1] Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia;Department of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia;Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia;Ethiopian Ministry of Health, Addis Ababa, Ethiopia;Malaria and Other Parasitological and Entomological Research Team, Bacterial, Parasitic and Zoonotic Diseases Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia;Malaria and Other Parasitological and Entomological Research Team, Bacterial, Parasitic and Zoonotic Diseases Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia;Institute of Infectious Disease and Global Health, University of North Carolina at Chapel Hill, Chapel Hill, USA;World Health Organization, Addis Ababa, Ethiopia;

关键词: Therapeutic efficacy;    Artemether-lumefantrine;    Uncomplicated malaria;    Ethiopia;   

DOI  :  10.1186/s12936-022-04436-8

 received in 2022-10-24, accepted in 2022-12-29,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundIn 2004, Ethiopia adopted artemether-lumefantrine (AL, Coartem®) as first-line treatment for the management of uncomplicated Plasmodium falciparum malaria. Continuous monitoring of AL therapeutic efficacy is crucial in Ethiopia, as per the World Health Organization (WHO) recommendation. This study aimed to assess the therapeutic efficacy of AL in the treatment of uncomplicated P. falciparum infection.MethodsA 28 day onearm, prospective evaluation of the clinical and parasitological response to AL was conducted at Shecha Health Centre, Arba Minch town, Southern Ethiopia. Patients were treated with six-dose regimen of AL over three days and monitored for 28 days with clinical and laboratory assessments. Participant recruitment and outcome classification was done in accordance with the 2009 WHO methods for surveillance of anti-malarial drug efficacy guidelines.ResultsA total of 88 study participants were enrolled and 69 of them completed the study with adequate clinical and parasitological response. Two late parasitological failures were observed, of which one was classified as a recrudescence by polymerase chain reaction (PCR). The PCRcorrected cure rate was 98.6% (95% CI 92.3–100). AL demonstrated a rapid parasite and fever clearance with no parasitaemia on day 2 and febrile cases on day 3. Gametocyte clearance was complete by day three. No serious adverse events were reported during the 28 days follow-up.ConclusionThe study demonstrated high therapeutic efficacy and good safety profile of AL. This suggests the continuation of AL as the first-line drug for the treatment of uncomplicated P. falciparum malaria in Ethiopia. Periodic therapeutic efficacy studies and monitoring of markers of resistance are recommended for early detection of resistant parasites.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq408.gif

Fig. 4

41116_2022_35_Article_IEq406.gif

12888_2022_4443_Article_IEq4.gif

41116_2022_35_Article_IEq398.gif